Physician profile
Deepa Mocherla
NPI 1649394909
$2,744.50
in general payments reported to CMS, 2019-2025
40 companies · $77.99 in 2025
The $77.99 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,113 · 2020: $327 · 2021: $58.47 · 2022: $47.58 · 2023: $121 · 2025: $77.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $121 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $120.80 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $316.50 | 2019-2020 | |
| Astellas Pharma US INC | $186.58 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $161.34 | 2019-2020 | |
| Seagen INC. | $153.82 | 2019-2023 | Tukysa |
| Pfizer INC. | $145.93 | 2019-2020 | |
| Incyte Corporation | $144.31 | 2019-2020 | |
| Janssen Biotech, INC. | $128.79 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $124.14 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $121.17 | 2019-2023 | |
| Abbvie INC. | $119.61 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $104.43 | 2019 | |
| Emd Serono, INC. | $84.64 | 2019-2020 | |
| Daiichi Sankyo INC. | $75.49 | 2019-2023 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $75.34 | 2019-2020 | |
| Eisai INC. | $69.67 | 2019-2020 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepa Mocherla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.